Regulatory News for August 2009

Cleveland BioLabs receives first U.S. patent allowance for its radiation protection drug, Protectan CBLB502 Cleveland BioLabs receives first U.S. patent allowance for its radiation protection drug, Protectan CBLB502

Cleveland BioLabs, Inc. announced recently that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/421,918, titled ‘Modulating Apoptosis’. Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502.
26 August, 2009